Maze Therapeutics CSBO Dandekar Atul exercised Options for 12,500 shares at $0 on Sep. 1, 2026. The transaction matters to investors because post-transaction ownership was recorded at 38,750 shares, while derivative securities ownership stood at 12,500 after the exercise was completed.
Key Highlights
- Dandekar Atul owned 12,500 derivative securities after the transaction.
- The transaction carried SEC transaction code M and occurred on Sep. 1, 2026.
- Dandekar Atul is identified in the filing as Maze Therapeutics’ CSBO.
Maze Therapeutics, Inc. (NASDAQ: MAZE) saw CSBO Dandekar Atul exercise options for 12,500 shares at $0 on Sep. 1, 2026. The transaction left Dandekar Atul with 38,750 shares, according to the post-transaction ownership record.
Option Exercise Details
The transaction was recorded under SEC transaction code M. Dandekar Atul exercised options covering 12,500 derivative securities of Maze Therapeutics on the same date. The exercise price for the shares was $0. Dandekar Atul is identified as Maze Therapeutics’ CSBO.
Post-Transaction Ownership
Following the exercise, Dandekar Atul’s reported ownership included 38,750 shares of Maze Therapeutics. The post-transaction record also showed ownership of 12,500 derivative securities.
FAQs
Q: What options did Dandekar Atul exercise at Maze Therapeutics?
A: Dandekar Atul exercised options for 12,500 Maze Therapeutics shares at an exercise price of $0. The transaction occurred on Sep. 1, 2026.
Q: How many Maze Therapeutics shares did Dandekar Atul own afterward?
A: Dandekar Atul’s post-transaction ownership was recorded at 38,750 Maze Therapeutics shares. The record followed the option exercise. The filing records this ownership after the 1 September 2026 exercise under SEC transaction code M.
Q: How many derivative securities did Dandekar Atul own after the exercise?
A: Dandekar Atul owned 12,500 derivative securities of Maze Therapeutics following the transaction. The exercise was recorded under SEC transaction code M.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.